# OnCo record paper-nct03897881-j-clin-oncol-2026-update (paper). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)". Whole corpus: https://onco.cc/api/v1/onco.nt
@prefix schema: <https://schema.org/> .
@prefix onco: <https://onco.cc/ns#> .
@prefix xsd: <http://www.w3.org/2001/XMLSchema#> .

<https://onco.cc/key-papers/paper-nct03897881-j-clin-oncol-2026-update/>
  a schema:ScholarlyArticle ;
  onco:kind "paper" ;
  schema:identifier "paper-nct03897881-j-clin-oncol-2026-update" ;
  schema:name "Intismeran Autogene Plus Pembrolizumab Versus Pembrolizumab Alone in High-Risk Resected Melanoma: 5-Year Update of the Randomized Phase IIb KEYNOTE-942 Study"@en ;
  schema:description "Later report from the trial registered as NCT03897881, in Journal of Clinical Oncology (2026); its title describes an updated or longer-term analysis."@en ;
  schema:url <https://onco.cc/key-papers/paper-nct03897881-j-clin-oncol-2026-update/> ;
  schema:dateModified "2026-09-22"^^xsd:date ;
  schema:citation <https://doi.org/10.1200/jco-26-00835>, <https://pubmed.ncbi.nlm.nih.gov/42223134/>, <https://europepmc.org/article/MED/42223134>, <https://clinicaltrials.gov/study/NCT03897881> ;
  onco:tag "europepmc-ingest" ;
  schema:sameAs <https://doi.org/10.1200/jco-26-00835> ;
  schema:datePublished "2026"^^xsd:gYear ;
  schema:author "Khattak A, Carlino MS, Meniawy T, et al." ;
  onco:trials <https://onco.cc/trials/nct03897881/> ;
  onco:journals <https://onco.cc/journals/jco/> .